Virbac: Q1 sales slip

(CercleFinance.com) - Virbac has posted Q1 2023 sales of E314.
8m down just 1% at real rates and down 1.3% at constant exchange rates, mainly due to an unfavourable comparison basis in a slowing market.

To a lesser extent, this quarter was also impacted by inventory effects at retailers at the end of 2022, in anticipation of the price increases carried out at the beginning of this year, the animal health group said.

At this stage, Virbac confirms its LFL annual sales growth forecast of 4% to 6%, and a ratio of current operating income before amortisation of assets from acquisitions to sales of around 13% to 14% at constant exchange rates.


Copyright (c) 2023 CercleFinance.com. All rights reserved.